DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities.
Saved in:
| Title: | DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities. |
|---|---|
| Authors: | Cai WY; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China., Cai XX; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China., Fei YR; The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China., Ye R; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China., Song DM; Department of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China., Hu D; Department of Clinical Lab, The Cixi Integrated Traditional Chinese and Western Medicine Medical and Health Group Cixi Red Cross Hospital, Cixi, China., Zhang WW; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China., Xia MF; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China., Yang XX; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Feb 06; Vol. 15, pp. 1534055. Date of Electronic Publication: 2025 Feb 06 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
